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Background. Long-term use of both zidovudine (AZT) and stavudine (d4T) is associated with lipoatrophy,
but it occurs possibly through different mechanisms.
Methods. Surgical biopsy specimens of subcutaneous adipose tissue were obtained from 18 human immu-
nodeficiency virus type 1 (HIV-1)–infected lipoatrophic patients (the LA+ group) who were treated with either
zidovudine (the AZT+LA+ group; ) or stavudine (the d4T+LA+ group; ) and from 10 nonlipoatrophicnp 10 np 8
HIV-1–infected patients (the LA group) who received antiretroviral therapy. Mitochondrial DNA (mtDNA) copy
numbers, gene expression, and immunohistochemistry data were analyzed.
Results. mtDNA copy numbers were significantly reduced in the LA+ group, compared with the LA group,
and in the d4T+LA+ group, compared with the AZT+LA+ group. The ratio of mtDNA-encoded cytochrome
COX3 to nuclear DNA–encoded COX4 expression was significantly lower in the LA+ group than in the LA
group. Compared with the LA group, the LA+ group had significantly lower expression of genes involved in
adipogenesis (SREBP1c and CEBPB), lipid (fatty acid synthase), and glucose (GLUT4) metabolism. Expression of
genes involved in mitochondrial biogenesis (PGC1B), apoptosis (FAS), inflammation (IL1B), oxidative stress (
PCNA and SOD1), and lamin B was significantly higher in the LA+ group than in the LA group. The d4T+LA+
group had significantly lower expression of genes involved in mitochondrial biogenesis (POLG1), energy metabolism
(the COX3/COX4 ratio), adipogenesis (SREBP1c and CEBPA), perilipin, and hexokinase than did the AZT+LA+
group. There were 7-fold more macrophages in adipose tissue specimens obtained from patients in the LA+ group,
compared with the LA group.
Conclusions. Lipoatrophy is characterized by mtDNA depletion, inflammation, and signs of apoptosis. Changes
were more profound in the d4T+LA+ group than in the AZT+LA+ group.
Abnormalities in body fat distribution (lipodystrophy)
are highly prevalent in human immunodeficiency virus
type 1 (HIV-1)–infected patients who are receiving
long-term treatment with antiretroviral drugs. Lipo-
atrophy (LA; i.e., loss of subcutaneous fat) is a clinical
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feature of the lipodystrophy syndrome and is associated
with metabolic complications [1, 2].
It has been suggested that nucleoside analogue re-
verse-transcriptase inhibitor (NRTI)–induced mito-
chondrial toxicity is the main pathophysiological
mechanism responsible for LA via inhibition of the
mitochondrial DNA (mtDNA) polymerase g (POLG)
[3]. Consistent with this hypothesis, mtDNA depletion
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Table 1. Primer sequences of the studied genes.
This table is available in its entirety in the online edition
of the Journal of Infectious Diseases
has been described in adipocyte cultures treated with antiret-
roviral drugs and in tissue samples obtained from lipoatrophic
patients, along with a decrease of mitochondrial respiratory
chain subunits and increased production of reactive oxygen
species [4]. Clinical trials have linked LA with long-term use
of the thymidine nucleoside analogues zidovudine (AZT) and
stavudine (d4T) [5].
In vitro studies show a hierarchy of different NRTIs that
interact with POLG [6, 7]. Although the active form of d4T is
efficiently incorporated in the nascent mtDNA by POLG and
causes chain termination, AZT has virtually no effect on
mtDNA chain elongation [8]. Nevertheless, AZT has been as-
sociated with mtDNA depletion [4], adipocyte apoptosis [4, 9],
and clinical LA [10]. This implies that AZT induces its mito-
chondrial toxicity via a POLG-independent mechanism.
Treatment with d4T results in more-severe LA than does
treatment with AZT [5]. We hypothesized that there may be
differences between AZT- and d4T-treated lipoatrophic patients
with regard to mtDNA copy numbers and expression of mi-
tochondria-encoded genes, as well as in nuclear transcripts in-
volved in mitochondrial biogenesis, adipogenesis, and meta-
bolic and endocrine function. Currently, there are little human
data comparing these 2 NRTIs in this regard [11]. In the present
study, we compared mtDNA content and gene expression in
highly active antiretroviral therapy (HAART)–treated patients
with and without LA. Moreover, we conducted a comparison
between AZT- and d4T-associated LA. Finally, an immunohis-
tochemical analysis was performed to compare the inflam-
matory state and vitality of lipoatrophic adipose tissue in AZT-
and d4T-associated LA.
MATERIALS AND METHODS
Patients. After approval by the ethics review committee and
provision of written and informed from the patients, clinically
stable HIV-1–infected adult patients were recruited from the
HIV outpatient clinic of the Helsinki University Central Hos-
pital (Helsinki, Finland). Lipoatrophic patients had to be
treated with HAART for at least 18 months, with no changes
in the regimen for the 12 weeks before the study, and had to
be taking either d4T or AZT. LA was defined as self-reported
and investigator-confirmed loss of subcutaneous fat, with or
without increased abdominal girth or breast size or develop-
ment of a buffalo hump. Patients with LA were participants in
a study examining the effects of uridine on LA, but all present
examinations were performed before the uridine and/or pla-
cebo intervention [12]. Nonlipoatrophic patients had to have
been taking HAART for a minimum of 18 months, with no
changes in the regimen for the 12 weeks prior to the study,
and to have not developed symptoms of LA (self-reported
and clinician-confirmed) while receiving antiretroviral therapy.
HIV-1–infected patients with LA who were taking HAART
(hereafter referred to as “the LA+ group”) were compared with
those who had not developed LA while receiving HAART (here-
after referred to as “the LA group”). We subdivided the LA+
group into a subgroup of patients who were taking d4T (here-
after referred to as “the d4T+LA+ group”) or AZT (hereafter
referred to as “the AZT+LA+ group”).
Measures of body composition. Limb, truncal, and total
body fat were measured using dual-energy x-ray absorptiometry
(Lunar Prodigy). Intra-abdominal and abdominal subcutane-
ous fat were quantified by analyzing 16 T1-weighted trans-axial
magnetic resonance images, as described elsewhere [13].
Subcutaneous fat biopsies. After administration of local an-
aesthesia with lidocaine, subcutaneous fat biopsy specimens were
surgically taken from the midpoint between the iliac crest and
the umbilicus. Part of the biopsy specimen was immediately
snap-frozen in liquid nitrogen, and 100 mg of tissue from each
patient was subsequently processed with trizol for RNA extrac-
tion. Another part of the biopsy was formalin fixed and paraffin
embedded for subsequent immunohistochemical analyses.
RNA extraction. One hundred mg of adipose tissue per
patient was homogenized using the Geneclean isolation kit
(Bio101 systems, Obiogene). RNA was extracted with the
RNeasy Lipid Tissue Kit (Qiagen) in accordance with the man-
ufacturer’s instructions. The quantity and integrity of RNA were
verified using RNA 6000 nanochips (Agilent2100 Bioanalyser).
For each sample 1.5 mg of RNA was used for reverse transcrip-
tion, employing 400 U of Superscript II (Invitrogen) and 100
mM of oligo(dT)12–18 (Invitrogen) as primer.
Real-time quantification of gene expression. Primer pairs
were designed in an intron-spanning fashion to avoid unspecific
amplification of contaminating genomic DNA, using the uni-
versal probe library from Roche (http://www.universalprobe
library.com). The complete list of primer sequences is available
in table 1, which appears only in the electronic version of the
Journal. Gene expression was quantified using the LightCycler
480 (Roche) on a 384-well plate. Ten-mL reactions contained
5 mL of SYBR Green I Master mix (Roche), 50 ng of cDNA
template, and 0.5 mM of each primer. Target genes were run
in duplicate on 1 plate, which included all patient samples plus
standard dilution curve of a glyceraldehyde-3-phosphate de-
hydrogenase plasmid (6 dilutions from a factor of 102 to 107)
plus a no-template control. Cycling conditions were as follows:
activation, 95C for 10 s; and 40 amplification cycles at 95C
for 10 s, 52C for 5 s, and 72C for 12 s. Polymerase chain
reaction conditions were optimized for linearity of amplifica-
tion for all primers in a dilution series. Melting curve analysis
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Table 2. Full and abbreviated names of genes included in the study and the function of the genes.
Abbreviation Gene Function
16SRNA 16S ribosomal RNA Mitochondrial transcription
36B4 Acidic ribosomal phosphoprotein P0 Housekeeping gene
ACTB Actin b Housekeeping gene
B2M b2 Microglobulin Housekeeping gene
CEBPA CCAAT/enhancer binding protein–a Early adipocyte differentiation
CEBPB CCAAT/enhancer binding protein–b Adipocyte differentiation
COX3 Cytochrome c oxidase subunit III Respiratory chain subunit
COX4 Cytochrome c oxidase subunit IV Respiratory chain subunit
FAS Factor of apoptotic stimulus Regulation of apoptosis
FASN Fatty acid synthase Lipid metabolism
GLUT4 Glucose transporter 4 Glucose metabolism
GPX1 Glutathione peroxidase transcript variant 1 Scavenging of reactive oxygen species
HEXOK1 Hexokinase 1 Glucose metabolism
IL1B Interleukin-1b Proinflammatory cytokine
IL6 Interleukin-6 Proinflammatory cytokine
LMNA Lamin A/C Nuclear DNA maturation, chromatin
organization
LMNB Lamin B Marker of cell proliferation
p53 Tumor protein p53 Regulation of apoptosis
PCNA Proliferating cell nuclear antigen Marker of cell proliferation
PGC1B Peroxisome proliferator–activated gamma coactivator 1b Mitochondrial transcription
PLIN Perilipin Lipid metabolism
POLG1 Polymerase g (catalytic subunit) Mitochondrial biogenesis
POLG2 Polymerase g (accessory subunit) Mitochondrial biogenesis
PPARG Peroxisome proliferator–activated receptor g Lipogenesis
PPARG2 Peroxisome proliferator–activated receptor g subunit 2 Lipogenesis
SOD1 Superoxide dismutase 1 (cytosolic) Scavenging of reactive oxygen species
SREBP1c Sterol regulatory element–binding protein 1c Lipogenesis
TFAM Mitochondrial transcription factor A Mitochondrial transcription
TNFA Tumor necrosis factor–a Proinflammatory cytokine
was performed to ensure that all investigated genes were rep-
resented by a single peak, indicating specificity. Gene expression
was calculated from the real-time polymerase chain reaction
efficiency [14] in relation to the mean of 3 housekeeping genes
(ACTB, 36B4, and B2M) that are commonly used [15]. Non-
regulation of the housekeeping genes was validated using
geNorm, version 3.4 (PrimerDesign) [16].
Gene expression analysis. All studied genes, with their full
and abbreviated names and brief function descriptions, are pro-
vided in table 2.
mtDNA copy numbers. Genomic DNA was extracted from
adipose tissue using the QIAamp DNA isolation kit (Qiagen).
mtDNA and nuclear DNA (nDNA) copy numbers were de-
termined by quantitative polymerase chain reaction using the
ABI 7700 sequence detection system (Applied Biosystems). We
amplified the mtDNA-encoded ATP synthase 6 gene between
nucleotide positions 8981 and 9061. mtDNA was quantified
with a FAM fluorophore–labelled probe (5′–6FAM-CCTAACC-
GCTAACATTACTGCAGGCC ACC-TAMRA-3′). For the de-
tection of nDNA, we selected exon number 8 of the glyceral-
dehyde-3-phosphate dehydrogenase gene between nucleotide
positions 4280 and 4342 and used a VIC fluorophore–labelled
probe (5′–VIC-CCCTGCCTCTACTGGCGCTGCC-TAMRA-
3′). Each 25-mL reaction contained 25 ng of genomic DNA, 100
nM of probe, 200 nM of primers, and TaqMan Universal Master
Mix (Applied Biosystems). Amplifications of mitochondrial
and nuclear products were separately performed in optical 96-
well plates (Applied Biosystems). An initial incubation at 50C
for 2 min was followed by 10 min at 95C and 40 denaturing
steps at 95C for 15 s, alternating with combined annealing
and/or extension at 60C for 1 min. All samples were run in
triplicate. Absolute mtDNA and nDNA copy numbers were
calculated using serial dilutions of plasmids with known copy
numbers.
Immunohistochemistry. Adipose tissue biopsy specimens
were used for immunohistochemical analysis. CD68 served as
a marker for macrophages and perilipin (PLIN) as a marker
for viable adipocytes [17]. Sectioning was performed using a
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standard protocol for formalin-fixed paraffin-embedded tissue
blocks. Consecutive serial sections were treated with xylene,
descending ethanol dilution series, and distilled water to dewax
the tissue samples. Thereafter, sections were microwave-treated
in 10 mM of citrate buffer (pH, 6.0) and washed alternately
with distilled water, hydrogen peroxide, and phosphate-buf-
fered saline with 0.25% Triton X-100 (pH, 7.2) to inactivate
endogenous staining. Nonspecific staining was reduced by ap-
plying normal goat serum (ratio, 1:5; Dako) to the sections for
30 min. Samples were then incubated for 1 h at room tem-
perature with mouse monoclonal anti-CD68 (ratio, 1:200;
Novocastra Laboratories) or guinea pig polyclonal anti-PLIN
(ratio, 1:1000; Acris Antibodies GmbH). For negative controls
of CD68 staining, mouse monoclonal isotypic control (ratio,
1:200; Abcam) was used as a primary antibody. For PLIN-
negative control, the primary antibody was omitted. After rins-
ing in phosphate-buffered saline–Triton X-100 buffer, sections
were incubated with biotinylated anti-mouse (ratio, 1:1500;
Vector Laboratories) or anti-guinea pig (ratio, 1:1500; Abcam)
secondary antibodies. Avidin-biotin peroxidase complexes
(Vector Laboratories) were added followed by visualization with
3,3-diaminobenzidine tetrachloride (Vector Laboratories). Af-
ter washes with distilled water, ascending ethanol series, and
xylene, sections were counterstained with Harris hematoxylin
(Histolab). For each sample, the number of macrophages,
crown-like structures and PLIN-free cells in the entire section
were counted using light microscopy and normalized for the
total section area. Macrophages were identified as CD68-pos-
itive cells, and crown-like structures were defined as 1 PLIN-
free adipocyte surrounded by 3 macrophages [17]. Mea-
surement of total section area using arbitrary units was
performed using Adobe Photoshop Elements, version 1.0.1
(Adobe Systems).
Statistical analysis. Demographic and clinical parameters
among the study groups were compared using Fisher’s exact
test for categorical variables and unpaired t test or the Wil-
coxon-Mann-Whitney test for continuous variables, as appro-
priate. Correlations were calculated using the Pearson’s prod-
uct-moment coefficient. P values were not adjusted for multiple
comparisons. For statistical analyses, we used Sigma Stat for
Windows software, version 3.0 (Jandel Corporation); GraphPad
Prism, version 3.02 (GraphPad Software); and Lotus 1–2-3 of
Lotus SmartSuite Release 9.5 (Lotus Development Corporation,
IBM Corporation). Data are presented as mean standard de-
viation. Two-tailed P values !.05 were considered to be statis-
tically significant.
RESULTS
Demographic and HIV-1 characteristics of the patients. The
LA+ and LA groups (table 3) were comparable with respect
to age, sex, duration of HIV-1 infection, CD4+ T cell count,
and HIV-1 RNA load. The LA+ group had significantly less
total limb fat and a longer history of antiretroviral therapy than
did the LA group.
With regard to the AZT+ and d4T+LA+ subgroups (table
3), the treatment-related characteristics were similar. The
d4T+LA+ group had a significantly lower body mass index and
less limb, truncal, and total fat, compared with the AZT+LA+
group. The amount of intra-abdominal fat was similar between
the LA subgroups.
Of the 18 patients with lipoatrophy, 10 received zidovudine
(AZT+LA+) and 8 received stavudine (d4T+LA+). In the
AZT+LA+ group, all patients received lamivudine, and 2 pa-
tients also received abacavir. All patients in the AZT+LA+ group
also received a protease inhibitor (PI); 2 patients received a
double-boosted PI regimen, and 2 received a PI plus a non-
NRTI (NNRTI). The following PIs and NNRTIs were pre-
scribed: ritonavir-boosted lopinavir ( ), amprenavirnp 8
( ), indinavir ( ), efavirenz ( ), and nevirapinenp 2 np 2 np 1
( ). In the d4T+LA+ group, 7 patients received lamivudinenp 1
and 1 patient received tenofovir plus abacavir. All 8 patients
received a PI (1 patient received a PI and an NNRTI). The
following PIs and NNRTIs were prescribed: ritonavir-boosted
lopinavir ( ), nelfinavir ( ), ritonavir-boosted indi-np 3 np 3
navir ( ), ritonavir-boosted saquinavir ( ), and efa-np 1 np 1
virenz ( ). In the LA group, all patients received lami-np 1
vudine, and 9 patients received zidovudine. In this group, 2
patients received a PI (1 received ritonavir-boosted lopinavir,
and 1 received nelfinavir), and 8 patients received an NNRTI
(4 received efavirenz, and 4 received nevirapine).
Fat histology. In adipose tissue specimens obtained from
patients in the LA+ group, there were 7-fold more macrophages
than specimens from the LA group ( vs.14.1 13.1 2.3
macrophages per 100,000 arbitrary area units; ) (fig-1.9 Pp .01
ure 1). The number of macrophages did not differ between the
LA subgroups. The number of crown-like structures and PLIN-
free cells did not differ between the LA+ and LA groups or
between the LA subgroups (figure 2).
mtDNA copy numbers. The mean amount of mtDNA was
significantly lower in the LA+ group than in the LA group
( vs. copies/cell; ). Further-238 129 585 558 Pp .009
more, the d4T+LA+ group had a significantly lower mean
mtDNA copy number, compared with did the AZT+LA+ group
( vs. copies/cell; ).139 59 317 115 Pp .001
Gene transcripts related to mitochondrial function.
Expression of several genes involved in the supply of respiratory
chain subunits—namely, the mtDNA-encoded cytochrome c
oxidase subunit 3 (COX3) and 16SRNA and the nDNA-en-
coded COX4. COX3 transcripts were slightly, but not signifi-
cantly, lower in the LA+ group than in the LA group, whereas
COX4 transcripts were significantly higher in the LA+ group
(table 4). These changes resulted in a significantly lower COX3/
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Table 3. Human immunodeficiency virus type 1 (HIV-1)–related and body composition characteristics of the study groups.
Characteristic
LA+ group
(n p 18)
LA group
(n p 10) P a
d4T+LA+ group
(n p 8)
AZT+LA+ group
(n p 10) P b
Demographic and HIV-1–related characteristics
Patient age, years 46.7  10.0 43.3  11.0 .42 49.3  11.9 44.6  8.2 .34
No. of female patients 3 1 1.99 1 2 1.99
Duration of HIV-1 infection, years 9.9  4.6 6.9  3.6 .09 8.2  3.4 11.2  4.9 .18
Duration of HAART, years 5.9  1.8 4.2  1.8 .02 6.0  1.5 5.8  2.1 .86
No. of patients with an HIV-1 RNA level
!50 copies/mL 15 10 .53 7 8 1.99
CD4+ T cell count, cells/mL 548  270 543  187 .96 592  248 513  294 .56
Receipt of zidovudine 10 9 .10 0 10 !.001
Receipt of stavudine 8 0 .03 8 0 !.001
Receipt of PI(s) 18 2 !.001 8 10 NA
Receipt of NNRTI(s) 3 8 !.001 1 2 1.99
Body composition
Weight, kg 73.6  13.3 75.0  10.8 .79 66.6  10.0 79.2  13.3 .04
BMI 23.5  3.4 23.5  2.8 .97 21.5  2.6 25.1  3.2 .02
Total limb fat, g 3243  2610 5750  2767 .03 1554  1474 4594  2572 .009
Total truncal fat, g 9546  4961 9377  4858 .93 6772  2495 11,766  5416 .03
Total fat, g 13,223  7444 15,683  7661 .43 8656  3891 16,876  7716 .02
Intra-abdominal fat, cm3 2171  1237 854  567 .004 1901  803 2388  1507 .42
NOTE. Data are mean  standard deviation, unless otherwise indicated. AZT+LA+ group, HIV-1–infected patients with lipoatrophy whose HAART regimen
included zidovudine; BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); d4T+LA+ group, HIV-1–infected patients
with lipoatrophy whose HAART regimen included stavudine; HAART, highly active antiretroviral therapy; LA+ group, HIV-1–infected patients with lipoatrophy who
were taking HAART; LA group, HIV-1–infected patients who had not developed lipoatrophy while receiving HAART; NA, not applicable; NNRTI, nonnucleoside
reverse-transcriptase inhibitor; PI, protease inhibitor.
a LA+ group vs. LA group.
b d4T+LA+ group vs. AZT+LA+ group.
COX4 ratio in the LA+ than the LA group (table 4). The
d4T+LA+ group had significantly lower expression of COX3
and 16SRNA, compared with the AZT+LA+ group (table 5).
Also, the COX3/COX4 ratio was significantly lower in the
d4T+LA+ group than in the AZT+LA+ group (table 5).
mtRNA per mtDNA template. To calculate the relative
number of RNA transcripts per molecule of mtDNA template,
we normalized mtDNA-encoded genes for the amount of
mtDNA molecules. Relative to the mtDNA copies per cell,
transcription of mtDNA-encoded genes was significantly high-
er in the LA+ group than in the LA group (table 6). This
effect was more pronounced (although the difference was sta-
tistically insignificant) in the d4T+LA+ group than in the
AZT+LA+ group (table 6).
Gene transcripts involved in mitochondrial biogenesis.
Polymerase g, an enzyme consisting of 2 subunits (POLG1 and
POLG2) and mitochondrial transcription factor A (TFAM),
which provides the replication primer, play a key role in the
regulation of mtDNA replication [18]. PPARG coactivator 1b
(PGC1B) stimulates mitochondrial gene transcription via ac-
tivation of TFAM [18] and enhances transcription of the per-
oxisome proliferator–activated receptor g (PPARG), thus rep-
resenting a link between mitochondrial biogenesis and adipose
cell function [19].
POLG1 and POLG2 transcription did not differ between the
LA+ and the LA groups (table 4). Expression of POLG1, but
not of POLG2, was significantly lower in the d4T+LA+ group
than in the AZT+LA+ group (table 5). TFAM expression was
comparable between all groups. The PGC1B transcripts were
7-fold higher in the LA+ group than in the LA group (table
4). There was no significant difference between the AZT+LA+
and d4T+LA+ groups with regard to PGC1B (table 5).
Adipogenesis. SREBP1c expression was lower in the LA+
group than in the LA group (table 4). Among all patients,
there was an inverse correlation between the expression of
SREBP1c and PGC1B ( ; ) and a positiverp0.58 Pp .002
correlation between SREBP1c expression and mtDNA copy
number ( ; ). CEBPA and SREBP1c transcriptrp 0.55 Pp .014
levels were lower in the d4T+LA+ group than in the AZT+LA+
group (table 5).
Lamin B (LMNB) expression was significantly increased in
the LA+ group, compared with the LA group (table 4). Ex-
pression of lamin A/C (LMNA) and LMNB was comparable
between the LA subgroups (table 5).
Lipid and glucose metabolism. The LA+ group had fewer
fatty acid synthase (FASN) and glucose transporter 4 (GLUT4)
transcripts did than the LA group (table 4). PLIN and
HEXOK1 transcripts were significantly lower in the d4T+LA+
Figure 1. Immunohistochemical staining with CD68. Macrophages are identified as CD68-positive cells (brown) in the adipose tissue. Original
magnification, 300. Representative images of zidovudine-associated lipoatrophy (upper left), stavudine-associated lipoatrophy (upper right), no lipo-
atrophy (lower left), and a CD68-negative control (lower right).
Figure 2. Immunohistochemical stainings with CD68 and perilipin. Macrophages are identified as CD68-positive cells (brown) in the adipose tissue.
Original magnification, 600. Images are of a representative crown-like structure (CLS) in a CD68-positive stain (upper left), the same CLS in the
CD68-negative control (upper right), the same CLS in the perilipin stain (lower left), and the perilipin-negative control of the same structure (lower
right). Note that the macrophage-encircled adipocyte, CLS, is lacking the perilipin immunoactivity in its membrane (blue instead of normal, viable
brown), a feature in literature classified as a sign of a nonviable adipocyte.
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Table 4. Relative expression of gene transcripts in comparison with the mean of 3 house-
keeping genes (actin b [ACTB]; b-2 microglobulin [B2M], and ribosomal phosphoprotein P0 [36B4])
for patients with versus patients without lipatrophy.
Gene
Mean  standard deviation
P
Direction
of changecLA+ groupa LA groupb
Housekeeping genes ACTB, B2M, and 36B4 1.05  0.36 1.00  0.17 .62 …
Mitochondrial energy metabolism
COX4 2.53  0.87 1.37  0.42 .001 Increase
COX3/COX4-ratio 0.33  0.16 0.89  0.35 !.001 Decrease
COX3 0.87  0.41 1.28  0.73 .07 …
16SRNA 0.70  0.34 0.72  0.33 .90 …
Mitochondrial biogenesis
PGC1B 6.74  6.94 0.95  0.32 .02 Increase
POLG2 1.24  0.28 1.09  0.12 .16 …
TFAM 1.30  0.50 1.22  0.16 .65 …
POLG1 1.21  0.44 1.19  0.12 .89 …
Adipogenesis
LMNB 1.39  0.75 0.61  0.43 .01 Increase
SREBP1c 0.40  0.32 1.98  1.15 !.001 Decrease
CEBPB 0.96  0.48 1.43  0.65 .046 Decrease
CEBPA 1.96  1.16 2.74  1.24 .12 …
PPARG2 1.72  0.85 1.40  0.31 .29 …
PPARG 1.82  1.07 1.48  0.44 .36 …
LMNA 1.26  0.55 1.05  0.18 .40 …
Lipid and glucose metabolism
FASN 3.64  3.79 9.67  2.82 !.001 Decrease
GLUT4 1.42  1.15 2.87  1.68 .015 Decrease
HEXOK1 1.21  0.54 1.42  0.26 .27 …
PLIN 1.03  1.04 1.37  0.58 .38 …
Apoptosis, inflammation and oxidative stress
IL1B 0.39  0.15 0.12  0.07 !.001 Increase
FAS 6.01  3.08 2.38  1.16 .002 Increase
SOD1 2.03  0.84 1.36  0.17 .03 Increase
PCNA 1.81  0.38 1.49  0.38 .046 Increase
IL6 0.35  0.60 0.01  0.02 .12 …
GPX1 1.84  1.07 1.31  0.36 .16 …
TNFA 0.80  1.23 0.23  0.21 .19 …
p53 1.02  0.35 1.09  0.26 .57 …
NOTE. CEBPA and CEBPB, CCAAT/enhancer binding protein a and b; COX3 and COX4, cytochrome c oxidase
subunit 3 and 4; FAS, factor of apoptotic stimulus; FASN, fatty acid synthase; GLUT4, glucose transporter 4; GPX1,
glutathione peroxidase 1; HEXOK1, hexokinase 1; IL1B and IL6, interleukin-1b and -6; LMNA and LMNB, lamin A/
C and B; p53, tumor protein p53; PGC1B, peroxisome proliferative-activated receptor gamma coactivator 1b; PCNA,
proliferating cell nuclear antigen; PLIN, perilipin; POLG1, polymerase g (catalytic subunit); POLG2, polymerase g
(accessory subunit); PPARG and PPARG2, peroxisome proliferative-activated receptor g and g subunit 2; 16SRNA,
16S ribosomal RNA; SOD1, superoxide dismutase 1; SREBP1c, sterol element binding transcription factor 1c; TFAM,
mitochondrial transcription factor A; TNFA, tumor necrosis factor–a.
a Human immunodeficiency virus type 1 (HIV-1)–infected patients with lipoatrophy who were taking highly active
antiretroviral therapy.
b HIV-1–infected patients who had not developed lipoatrophy while receiving highly active antiretroviral therapy.
c Direction of change in gene expression is indicated as the LA+ group versus the LA group.
group than in the AZT+LA+ group (table 5). Among all pa-
tients, GLUT4 expression correlated positively with both FASN
( ; ) and HEXOK1 ( ; ).rp 0.73 P ! .001 rp 0.64 P ! .001
Apoptosis, inflammation, and oxidative stress. The factor
of apoptotic stimulus (FAS) receptor is a key regulator of ap-
optosis due to extrinsic stress signals. Because the extrinsic stress
signals do not affect the mRNA concentrations of p53 but,
rather, regulate p53 posttranslationally [20], the gene was used
as a control for stress-related apoptotic mRNA alterations. We
also analyzed superoxide dismutase 1 (SOD1) and glutathione
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Table 5. Relative expression of gene transcripts in comparison with the mean of 3 housekeeping
genes (actin b [ACTB]; b-2 microglobulin [B2M], and ribosomal phosphoprotein P0 [36B4]) for patients
with lipoatrophy who received zidovudine versus stavudine.
Gene
Mean  standard deviation
P
Direction
of changecd4T+LA+ groupa AZT+LA+ groupb
Housekeeping genes ACTB, B2M, and 36B4 1.06  0.37 1.04  0.36 .49 …
Mitochondrial energy metabolism
COX3/COX4-ratio 0.24  0.09 0.43  0.16 .02 Decrease
COX3 0.64  0.24 1.06  0.43 .03 Decrease
16SRNA 0.50  0.19 0.86  0.36 .03 Decrease
COX4 2.77  0.89 2.29  0.86 .60 …
Mitochondrial biogenesis
POLG1 0.93  0.38 1.41  0.37 .01 Decrease
TFAM 1.38  0.67 1.24  0.32 .57 …
POLG2 1.20  0.16 1.26  0.34 .64 …
PGC1B 6.52  6.89 6.90  7.34 .96 …
Adipogenesis
CEBPA 1.29  0.58 2.50  1.25 .02 Decrease
SREBP1c 0.25  0.37 0.47  0.28 .04 Decrease
LMNA 1.09  0.60 1.44  0.45 .14 …
CEBPB 0.78  0.34 1.11  0.54 .15 …
PPARG2 1.43  0.74 1.95  0.90 .18 …
PPARG 1.58  1.03 2.01  1.11 .48 …
LMNB 1.50  0.79 1.33  0.76 .67 …
Lipid and glucose metabolism
HEXOK1 0.86  0.51 1.48  0.40 .007 Decrease
PLIN 0.53  0.71 1.52  1.13 .04 Decrease
GLUT4 0.90  0.52 1.78  1.34 .11 …
FASN 3.00  3.59 4.22  4.07 .26 …
Apoptosis, inflammation and oxidative stress
GPX1 1.35  0.41 2.18  1.27 .10 …
PCNA 1.94  0.46 1.70  0.27 .10 …
SOD1 1.71  0.58 2.29  0.95 .16 …
FAS 6.65  2.98 5.51  3.22 .34 …
TNFA 0.42  0.61 1.09  1.53 .38 …
p53 0.97  0.45 1.05  0.27 .45 …
IL6 0.27  0.28 0.42  0.83 .66 …
IL1B 0.38  0.18 0.40  0.14 .85 …
NOTE. CEBPA and CEBPB, CCAAT/enhancer binding protein a and b; COX3 and COX4, cytochrome c oxidase subunit
3 and 4; FAS, factor of apoptotic stimulus; FASN, fatty acid synthase; GLUT4, glucose transporter 4; GPX1, glutathione
peroxidase 1; HEXOK1, hexokinase 1; IL1B and IL6, interleukin-1b and -6; LMNA and LMNB, lamin A/C and B; PCNA,
proliferating cell nuclear antigen; p53, tumor protein p53; PGC1B, peroxisome proliferative-activated receptor gamma coac-
tivator 1b; PLIN, perilipin; POLG1, polymerase g (catalytic subunit); POLG2, polymerase g (accessory subunit); PPARG and
PPARG2, peroxisome proliferative-activated receptor g and g subunit 2; 16SRNA, 16S ribosomal RNA; SOD1, superoxide
dismutase 1; SREBP1c, sterol element binding transcription factor 1c; TFAM, mitochondrial transcription factor A; TNFA,
tumor necrosis factor-a.
a Human immunodeficiency virus type 1 (HIV-1)–infected patients with lipoatrophy whose highly active antiretroviral
regimen included stavudine.
b HIV-1–infected patients with lipoatrophy whose highly active antiretroviral regimen included zidovudine.
c Direction of change in gene expression is indicated as the d4t+LA+ group versus the AZT+LA+ group.
peroxidase 1 (GPX1) expression as indicators of oxidative stress
[21,22]. The proliferating cell nuclear antigen (PCNA) was eval-
uated as a marker of adipocyte cycling.
The expression of FAS, but not of p53, was increased in the
LA+ group, compared with the LA group (table 4). The level
of SOD1 and PCNA gene expression was higher in the LA+
group than in the LA group (table 5). Of the inflammatory
cytokines, expression of IL1B was greater in the LA+ group
than in the LA group (table 4). IL1B transcripts correlated
inversely with mtDNA copy numbers ( ; ).rp0.42 Pp .005
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Table 6. Expression of mitochondrial DNA-encoded transcripts in the patient groups.
Gene
Mean  standard deviation
P a
Mean  standard deviation
P b
LA+ group
(n p 18)
LA group
(n p 10)
d4T+LA+ group
(n p 8)
AZT+LA+ group
(n p 10)
16SRNA RNA 0.34  0.18 0.15  0.05 .004 0.42  0.23 0.28  0.08 .07
COX3 RNA 0.42  0.20 0.25  0.08 .02 0.52  0.24 0.35  0.11 .058
NOTE. AZT+LA+ group, HIV-1–infected patients with lipoatrophy whose highly active antiretroviral therapy
(HAART) regimen included zidovudine; COX3, cytochrome c oxidase subunit 3; d4T+LA+ group, HIV-1–infected
patients with lipoatrophy whose HAART regimen included stavudine; LA+ group, HIV-1–infected patients with
lipoatrophy who were taking HAART; LA group, HIV-1–infected patients who had not developed lipoatrophy while
receiving HAART; 16SRNA, 16S ribosomal RNA.
a For the LA+ group versus the LA group.
b For the d4t+LA+ group versus the AZT+LA+ group.
There were no statistically significant differences in the ex-
pression of markers of apoptosis, inflammation, and oxidative
stress between the AZT+LA+ group and the d4T+LA+ group
(table 5).
DISCUSSION
We compared gene expression and immunohistochemical signs
of inflammation in subcutaneous abdominal adipose tissue bi-
opsy specimens obtained from HIV-1–infected patients with
and without HAART-associated lipoatrophy. We were partic-
ularly interested in comparing the lipoatrophic patients using
either AZT or d4T.
In keeping with previous studies, we found mtDNA to be
depleted in the LA+ group, compared with the LA group
[23, 24]. In addition, the mtDNA-encoded COX3 expression
was decreased in patients with lipoatrophy, especially in those
with d4T-associated lipoatrophy. nDNA-encoded COX4 ex-
pression was increased in both treatment subgroups. POLG1
expression, unlike that of POLG2, was lower in the d4T+LA+
group than in the AZT+LA+ group. This may, in part, explain
the more severe mtDNA depletion in the d4T+LA+ group than
in the AZT+LA+ group.
Mitochondrial toxicity may induce oxidative stress in adipose
tissue, consequently contributing to impaired adipocyte differ-
entiation, increased inflammation, and activation of apoptosis
[25]. Accordingly, in the current study, we found a positive
correlation between mtDNA copy number and SREBP1c ex-
pression (an important transcription factor in adipogenesis)
and an inverse correlation between mtDNA copy number and
the expression of IL1B.
An increase in mitochondrial gene expression relative to the
number of mtDNA copies per cell in the LA+ group may reflect
an attempt to compensate for mtDNA depletion. The markedly
higher gene expression of PGC1B supports this line of reason-
ing. Expression of TFAM, however, was not altered in our LA
subgroups, although in healthy individuals, even short-term
exposure to AZT and d4T is associated with up-regulation of
PGC1B and TFAM mRNA [26].
With respect to expression of genes involved in adipogenesis,
we confirmed decreased SREBP1c expression in the LA+ group,
compared with the LA group [27, 28]. We now extended this
finding to both LA subgroups. Expression of PPARG was un-
changed, as was reported in some [29] but not all [27, 30]
previous studies.
Expression of CEBPB was significantly lower in the LA+
group than in the LA group. CEBPA followed the same trend.
Down-regulation of these genes was more prominent in the
d4T+LA+ group than in the AZT+LA+ group. These findings
are in accordance with previous reports of decreased expression
of CEPBA and CEBPB in patients with HAART-associated li-
poatrophy [27, 28].
We found GLUT4 gene expression to be decreased in the
LA+ group, compared with the LA group, which is in keeping
with our own previous findings [31] and with those of others
[27]. Expression of GLUT4 did not significantly differ between
the LA subgroups, although it tended to be lower in the
d4T+LA+ group than in the AZT+LA+ group.
LMNA and LMNB expression was analyzed because it has
been postulated that PI treatment may alter LMNA maturation
and, thus, inhibit translocation of SREBP1c from the cytoplasm
to the nucleus in LA [32]. We could not confirm decreased
LMNA gene expression in LA. We found significantly higher
expression of LMNB in the LA+ group than in the LA group.
The relationship between altered lamin maturation and stability
as well as the reduced SREBP1c translocation through nuclear
pores, which was previously observed with PI exposure [32],
has also been recently challenged [33].
Adipose tissue in lipoatrophic patients has been suggested
to be chronically inflamed [34]. An increased number of foamy
histiocytes [35] and immunohistochemically identified CD68-
positive macrophages has been reported in adipose tissue spec-
imens obtained from lipoatrophic patients [34]. However, in
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these studies, patients with LA were compared with HIV-1–
negative subjects. We have previously described increased ad-
ipose tissue inflammation in a different group of HIV-1–pos-
itive, HAART-treated, lipodystrophic patients who were com-
pared with HIV-1–positive, HAART-treated, nonlipodystrophic
patients [36]. In the current study, these findings are confirmed.
Proinflammatory cytokines impair adipocyte metabolism
and induce insulin resistance and apoptosis in adipose tissue
[37]. Apoptosis in the context of HAART-associated LA has
previously been described in vitro [4] and in vivo [38]. We
found that FAS was increased in the LA+ group, compared
with the LA group. The expression of p53 did not differ
between the groups, which is consistent with the predominantly
posttranscriptional activation of the p53 network [20]. With
regard to TNFA—a trigger of the extrinsic pathway of apopto-
sis—there was no difference between the d4T+LA+ and the
AZT+LA+ groups, although there was a trend towards in-
creased TNFA expression in the AZT+LA+ group, as previously
observed [38]. The increase of IL1B and TNFA transcripts could
originate from either recruited macrophages or inflamed adi-
pocytes [39, 40].
Compared with the LA+ group, no significant up-regulation
of SOD1 was evident in the LA group, and GPX1 followed
the same pattern. In comparison, for the treatment subgroups,
both of those genes tended to be more prevalent in the
AZT+LA+ group. This finding may reflect the particular pro-
pensity of AZT to induce reactive oxygen species production
[41].
The present study has several limitations. As with any cross-
sectional study, only an association, not a causal relationship,
can be demonstrated. Because of the limited group size, neg-
ative results should be interpreted with caution. It should also
be emphasized that mRNA profiles do not equal protein ex-
pression and that statistical analyses were not corrected for
multiple comparisons. It is also possible that the imbalance in
the use of PIs between the LA+ and the LA groups may have
affected the results. Although in vitro models have shown PI-
induced inhibition of adipocyte differentiation both by PPARg-
dependent [42] and PPARg-independent [43] mechanisms,
cessation of PI therapy, as opposed to cessation of NRTI ther-
apy, does not lead to improvement of lipoatrophy [44].
In summary, the present study demonstrates alterations in
gene expression in adipose tissue of patients with HAART-
associated LA, compared to HAART-treated, nonlipoatrophic
patients. The results confirm previous findings of mtDNA de-
pletion, inflammation, and disturbances in adipogenesis in li-
poatrophic fat. Furthermore, an excessive number of macro-
phages in lipoatrophic adipose tissue was demonstrated. When
comparing the d4T- and the AZT-treated lipoatrophic patients,
more severe mtDNA depletion and decrease in gene expression
of mtDNA-encoded COX3, nuclear adipogenic transcription
factors, and PLIN was found in patients with d4T-associated
lipoatrophy.
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